TGW 101
Alternative Names: TGW-101Latest Information Update: 26 Jun 2023
At a glance
- Originator Tagworks Pharmaceuticals
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoglobulin Fv fragments; Immunotoxins; Recombinant proteins
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 26 Jun 2023 Preclinical trials in Solid tumours in Netherlands (Parentral, controlled release) prior to June 2023 (Tagworks Pharmaceuticals pipeline, June 2023)